Phaseline

Companies › Tyra Biosciences

Tyra Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 4 Phase 1, 3 Phase 2; Oncology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dabogratinib (TYRA-300)
FGFR3-selective tyrosine kinase inhibitor
FGFR3Phase 2Low-grade NMIBC; Achondroplasia; Low Grade Upper Tract Urothelial Carcinoma; Healthy …Nov 2026
TYRA-200
FGFR 1/2/3 tyrosine kinase inhibitor
FGFR1, FGFR2, FGFR3Phase 1Locally Advanced CholangiocarcinomaMar 2027
TYRA-430
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 1Metastatic Hepatocellular CarcinomaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06006702Dabogratinib (TYRA-300)Phase 1HealthyOtherMay 2025
NCT05544552Dabogratinib (TYRA-300)Phase 1Locally Advanced Urothelial CarcinomaOncologyNov 2026
NCT06160752TYRA-200Phase 1Locally Advanced CholangiocarcinomaOncologyMar 2027
NCT06915753TYRA-430Phase 1Metastatic Hepatocellular CarcinomaOncologyJan 2028
NCT06995677Dabogratinib (TYRA-300)Phase 2Low-grade NMIBCOncologyFeb 2028
NCT06842355Dabogratinib (TYRA-300)Phase 2AchondroplasiaOtherJan 2030
NCT07265947Dabogratinib (TYRA-300)Phase 2Low Grade Upper Tract Urothelial CarcinomaOncologyOct 2030

From the company's SEC filings

Cash of $456m on 2026-09-30; operating cash outflow about $129m a year; runway about 42 months at that burn, to Apr 2030; 2 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

FGFR3 (3) FGFR1 (2) FGFR2 (2) FGFR4 (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Taiho Oncology Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Hutchmed Eisai Cogent Biosciences Xynomic Pharmaceuticals

Companies built like this

Elevar Therapeutics TransThera Sciences (Nanjing) TScan Therapeutics Radiopharm Theranostics Relay Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.